Validation of direct AMP kinase (AMPK) activation for treatment of X-linked Adrenoleukodystrophy

2021 ◽  
Vol 429 ◽  
pp. 119372
Author(s):  
Pierre-Axel Monternier ◽  
Jaspreet Singh ◽  
Pascale Gluais ◽  
David Moller ◽  
Sophie Bozec
Keyword(s):  
Antioxidants ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 776
Author(s):  
Elzbieta Janda ◽  
Concetta Martino ◽  
Concetta Riillo ◽  
Maddalena Parafati ◽  
Antonella Lascala ◽  
...  

Dietary flavonoids stimulate autophagy and prevent liver dysfunction, but the upstream signaling pathways triggered by these compounds are not well understood. Certain polyphenols bind directly to NRH-quinone oxidoreductase 2 (NQO2) and inhibit its activity. NQO2 is highly expressed in the liver, where it participates in quinone metabolism, but recent evidence indicates that it may also play a role in the regulation of oxidative stress and autophagy. Here, we addressed a potential role of NQO2 in autophagy induction by flavonoids. The pro-autophagic activity of seven flavonoid aglycons correlated perfectly with their ability to inhibit NQO2 activity, and flavones such as apigenin and luteolin showed the strongest activity in all assays. The silencing of NQO2 strongly reduced flavone-induced autophagic flux, although it increased basal LC3-II levels in HepG2 cells. Both flavones induced AMP kinase (AMPK) activation, while its reduction by AMPK beta (PRKAB1) silencing inhibited flavone-induced autophagy. Interestingly, the depletion of NQO2 levels by siRNA increased the basal AMPK phosphorylation but abrogated its further increase by apigenin. Thus, NQO2 contributes to the negative regulation of AMPK activity and autophagy, while its targeting by flavones releases pro-autophagic signals. These findings imply that NQO2 works as a flavone receptor mediating autophagy and may contribute to other hepatic effects of flavonoids.


Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Kenneth McGaffin ◽  
Benjamin Burkhead ◽  
Gregory Gibson ◽  
Christine Moravec ◽  
Charles McTiernan

Introduction: The failing heart displays contractile dysfunction, increased workload and energy demands, and a switch in substrate utilization for ATP production from free fatty acid to glucose oxidation. ATP production is regulated by AMP Kinase (AMPK). In skeletal muscle, the cytokines leptin (OB) and adiponectin (AD) stimulate AMPK activity and result in preferential glucose metabolism. Both OB and AD are elevated in human heart failure (HF), but it is unknown whether these cytokines may alter AMPK activation in the failing and/or mechanically unloaded heart. Hypothesis : In human HF, elevated OB and AD levels: 1) are in part due to increased production by the cardiomyocyte; 2) are associated with cardiac AMPK activation; and 3) are downregulated under conditions of reduced workload and ATP requirement such as occurs with mechanical unloading. Methods/Results: Left ventricular tissue was obtained from 5 non-failing (NF), 10 end stage failing (F), and 8 paired pre/post ventricular assist device (VAD) patients. Results reported are fold change ± SEM relative to NF or pre VAD, compared by t-test . Relative to NF, F hearts showed (Real-time PCR) increased mRNA for BNP (4.4±0.4, P =0.04), OB (5.4±0.3, P =0.03), OBR (7.3±0.2, P =0.01) and AD (9.1±0.9, P =0.01), while levels of an unrelated gene, the grehlin receptor, were decreased (0.10±0.01, P =0.01). Immunoblotting confirmed similar changes in OB, OBR and AD protein levels, and immunoflurescence localized these proteins to the cardiomyocyte. Increased activation of AMPKα was observed in F hearts (1.9±0.2 fold increase vs NF, P =0.02) as assessed by the ratio of phosphorylated to total AMPKα. In paired pre and post VAD supported hearts, these changes were reversed after mechanical unloading as decreased BNP (0.020±0.001, P =0.01), OB (0.030±0.001, P =0.03), OBR (0.25±0.01, P =0.02) and AD (0.22±0.01, P =0.04) mRNAs were seen relative to the pre VAD state, whereas increased grehlin receptor mRNA was observed (7.6±0.5, P <0.01 ) Further, relative to the pre VAD heart, post VAD showed a 1.7±0.2 fold ( P =0.04) decrease in the activation of AMPK. Conclusions: OB and AD are produced by failing cardiomyocytes and may contribute to preferential use of glucose for energy production in HF through activation of AMPK.


2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Ayesha Saleem ◽  
Michael Shuen ◽  
David A. Hood

2015 ◽  
Vol 308 (7) ◽  
pp. H749-H758 ◽  
Author(s):  
Giselle Barreto-Torres ◽  
Jessica Soto Hernandez ◽  
Sehwan Jang ◽  
Adlín R. Rodríguez-Muñoz ◽  
Carlos A. Torres-Ramos ◽  
...  

AMP kinase (AMPK) plays an important role in the regulation of energy metabolism in cardiac cells. Furthermore, activation of AMPK protects the heart from myocardial infarction and heart failure. The present study examines whether or not AMPK affects the peroxisome proliferator-activated receptor-α (PPARα)/mitochondria pathway in response to acute oxidative stress in cultured cardiomyocytes. Cultured H9c2 rat embryonic cardioblasts were exposed to H2O2-induced acute oxidative stress in the presence or absence of metformin, compound C (AMPK inhibitor), GW6471 (PPARα inhibitor), or A-769662 (AMPK activator). Results showed that AMPK activation by metformin reverted oxidative stress-induced inactivation of AMPK and prevented oxidative stress-induced cell death. In addition, metformin attenuated reactive oxygen species generation and depolarization of the inner mitochondrial membrane. The antioxidative effects of metformin were associated with the prevention of mitochondrial DNA damage in cardiomyocytes. Coimmunoprecipitation studies revealed that metformin abolished oxidative stress-induced physical interactions between PPARα and cyclophilin D (CypD), and the abolishment of these interactions was associated with inhibition of permeability transition pore formation. The beneficial effects of metformin were not due to acetylation or phosphorylation of PPARα in response to oxidative stress. In conclusion, this study demonstrates that the protective effects of metformin-induced AMPK activation against oxidative stress converge on mitochondria and are mediated, at least in part, through the dissociation of PPARα-CypD interactions, independent of phosphorylation and acetylation of PPARα and CypD.


2019 ◽  
Vol 476 (24) ◽  
pp. 3687-3704 ◽  
Author(s):  
Aphrodite T. Choumessi ◽  
Manuel Johanns ◽  
Claire Beaufay ◽  
Marie-France Herent ◽  
Vincent Stroobant ◽  
...  

Root extracts of a Cameroon medicinal plant, Dorstenia psilurus, were purified by screening for AMP-activated protein kinase (AMPK) activation in incubated mouse embryo fibroblasts (MEFs). Two isoprenylated flavones that activated AMPK were isolated. Compound 1 was identified as artelasticin by high-resolution electrospray ionization mass spectrometry and 2D-NMR while its structural isomer, compound 2, was isolated for the first time and differed only by the position of one double bond on one isoprenyl substituent. Treatment of MEFs with purified compound 1 or compound 2 led to rapid and robust AMPK activation at low micromolar concentrations and increased the intracellular AMP:ATP ratio. In oxygen consumption experiments on isolated rat liver mitochondria, compound 1 and compound 2 inhibited complex II of the electron transport chain and in freeze–thawed mitochondria succinate dehydrogenase was inhibited. In incubated rat skeletal muscles, both compounds activated AMPK and stimulated glucose uptake. Moreover, these effects were lost in muscles pre-incubated with AMPK inhibitor SBI-0206965, suggesting AMPK dependency. Incubation of mouse hepatocytes with compound 1 or compound 2 led to AMPK activation, but glucose production was decreased in hepatocytes from both wild-type and AMPKβ1−/− mice, suggesting that this effect was not AMPK-dependent. However, when administered intraperitoneally to high-fat diet-induced insulin-resistant mice, compound 1 and compound 2 had blood glucose-lowering effects. In addition, compound 1 and compound 2 reduced the viability of several human cancer cells in culture. The flavonoids we have identified could be a starting point for the development of new drugs to treat type 2 diabetes.


2013 ◽  
Author(s):  
Min-Seon Kim ◽  
Ghi-Su Kim ◽  
Hyuckki Chang ◽  
Mi-Seon Shin ◽  
Hyun Kyong Kim

Sign in / Sign up

Export Citation Format

Share Document